
An investigation on behalf of investors of Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) shares over potential securities laws violations by Catalyst Pharmaceutical Partners, Inc. and certain of its directors and officers in connection certain statements over its drug Firdapse was announced.